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Background: Glucose-6-phosphate dehydrogenase (G6PD), elevated in tumor cells, catalyzes the first reaction in
the pentose-phosphate pathway. The regulation mechanism of G6PD and pathological change in human
melanoma growth remains unknown.
Methods: HEM (human epidermal melanocyte) cells and human melanoma cells with the wild-type G6PD gene
(A375-WT), G6PD deficiency (A375-G6PDΔ), G6PD cDNA overexpression (A375-G6PDΔ-G6PD-WT), and mutant G6PD
cDNA (A375-G6PDΔ-G6PD-G487A) were subcutaneously injected into 5 groups of nude mice. Expressions of G6PD,
STAT3, STAT5, cell cycle-related proteins, and apoptotic proteins as well as mechanistic exploration of STAT3/STAT5
were determined by quantitative real-time PCR (qRT-PCR), immunohistochemistry and western blot.
Results: Delayed formation and slowed growth were apparent in A375-G6PDΔ cells, compared to A375-WT cells.
Significantly decreased G6PD expression and activity were observed in tumor tissues induced by A375-G6PDΔ,
along with down-regulated cell cycle proteins cyclin D1, cyclin E, p53, and S100A4. Apoptosis-inhibited factors Bcl-2
and Bcl-xl were up-regulated; however, apoptosis factor Fas was down-regulated, compared to A375-WT cells.
Moderate protein expressions were observed in A375-G6PDΔ-G6PD-WT and A375-G6PDΔ-G6PD-G487A cells.
Conclusions: G6PD may regulate apoptosis and expression of cell cycle-related proteins through phosphorylation
of transcription factors STAT3 and STAT5, thus mediating formation and growth of human melanoma cells. Further
study will, however, be required to determine potential clinical applications.
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transcription activatorBackground
Glucose-6-phosphate dehydrogenase (G6PD) is a critical
enzyme in mammalian erythrocytes that catalyzes the
first reaction in the pentose-phosphate pathway [1].
G6PD abnormalities affect as much as 7.5% of the global
population, with a wide range of occurrence based on
geographic distribution. These abnormalities occur in as* Correspondence: Zhuyuechun20091119@126.com
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reproduction in any medium, provided the orlittle of 0.1% of certain Japanese populations to more
than 35% in some African and European populations [2].
In fact, G6PD was the first prevalent enzyme deficiency
to be characterized by the World Health Organization
(WHO) in 1984 [3]. Around the world, between 140 and
160 distinct G6PD mutations have been reported [1].
In China, at least 24 mutations have been detected in
the G6PD gene [4,5]. Our previous study showed that
G6PD Mahidol (487G>A) was the most common G6PD
variant in the Achang ethnic group of Yunnan Province
[6]. Otherwise, G6PD Mahidol is a common deficient
variant caused by a (163)glycine-serine mutation thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Southeast Asia [7,8]. The prevalence of this mutation
can be accounted for by strong positive selection over
the past 1500 years that occurred in response to certain
parasites, including malaria-causing agents such as
Plasmodium vivax and Plasmodium falciparum, that
target humans [9]. Like many mutations involved in
parasitic resistance, G6PD Mahidol is a relatively recent
polymorphism generally referred to as a ‘loss-of-function’
mutation, occurring via a single-nucleotide change and
ultimately resulting in reduced G6PD production [10].
While G6PD Mahidol may confer a selective advantage to
parasitic infections, such as malaria, this genetic variation
may also have other detrimental affects to the immune
response and may be implicated in the cell cycle of abnor-
mal or cancerous cells [9,10].
It has been found that the expression or enzyme acti-
vity of G6PD is elevated in multiple tumors, including
leukemia [11], gastrointestinal cancers [12], renal cell
carcinomas [13], colon cancers [14], breast cancers [15],
endometrial carcinomas [16], prostate and liver cancer
[17,18]. Considering that ectopic G6PD expression
increases the levels of nicotinamide adenosine dinu-
cleotide phosphate (NAPDH) and glutathione, G6PD
may promote the survival of tumor cells through main-
tenance of both extracellular pH and redox potential
[19,20], though little is known about how G6PD regu-
lates cell proliferation and apoptosis in tumors.
Persistent expression and excessive activation of
STAT3 and STAT5 is apparent in melanoma cells. Ac-
cordingly, STAT3 and STAT5 have become interesting
potential target molecules for the treatment of mela-
noma [21,22]. Our previous in vitro study demonstrated a
significant reduction in the P-STAT5/STAT5 ratio of
A375-G6PDΔ cells following knockdown of G6PD in
A375 cells, while the P-STAT5/STAT5 ratio significantly
increased following overexpression of G6PD in the G6PD-
knockdown A375 cells. This suggested that G6PD pro-
motes the proliferation of A375 cells and is associated
with induction or activation of STAT5. In addition, it has
been found that STAT3 is persistently activated, and P-
STAT3 expression is significantly elevated in A375 cells.
STAT3 expression increased by five-fold in G6PD-
knockdown A375 cells compared to normal A375 cells,
and P-STAT3 expression levels in G6PD-knockdown
A375 cells was 20% of that in A375-WTcells (unpublished
data). The activation of STAT3 is fast and transient under
normal physiological conditions, and it is strictly regulated
[23]. These findings indicate that STAT3 and STAT5 play
important roles in mediating the biological characteristics
of melanomas. However, the underlying mechanism
remains unclear.
The current study further explores the relationship
and mechanism of action of G6PD and melanoma cellproliferation and apoptosis using a mouse model of
tumor formation. Human dermal melanoma cells
expressing the wild-type G6PD gene (A375-WT), G6PD-
deficient A375 cells (A375-G6PDΔ), and A375-G6PDΔ
cells with overexpression of normal G6PD cDNA (A375-
G6PDΔ-G6PD-WT) and mutant G6PD cDNA (A375-
G6PDΔ-G6PD-G487A) were administered to mice in
order to compare the time of initial tumor formation,
tumor size, and pathological changes. In addition, the
expression of G6PD and its activity, cell cycle-related
proteins, apoptosis-related proteins, and STAT3/STAT5
in tumor tissues were determined in order to provide
full documentation of the regulatory mechanisms
involved with in vivo melanoma growth associated with
G6PD.Methods
Cell culture
Human melanoma cell lines (A375) with knocked down
G6PD genes (A375-G6PDΔ) were established from wild-
type human dermal melanoma cell lines (A375-WT)
(Cell Bank of the Chinese Academy of Sciences) as
previously described [24]. Wild-type and mutant-type
G6PD genes (G487A,G→A) were amplified using PCR
and then cloned into a retroviral vector (pBABEpuro) to
yield the expression vectors pBABEpuro-G6PDWT and
pBABE-puro-G6PDG487A, respectively. The expression
vectors were transfected into 293FT package cells
(R70007, Invitrogen, USA) using a retrovirus packaging
kit (D6161, Takara, Japan) to produce recombinant
viruses. The recombinant retrovirus was used to infect
the A375-G6PDΔ cells and was subsequently screened
for 7 days using puromycin (0.5 μg/mL) (J593, Amreso,
USA). Then, clones positive for puromycin-resistance
were co-cultured in G418 (200 μg/mL) and puromycin
(0.25 μg/mL) to yield A375Δ-WT and A375Δ-G6PDA
cells exhibiting overexpression of G6PD. The passage
and digestion of cells were similar to those of the A375-
G6PDΔ cells. Normal human epidermal melanocytes
(HEM) were isolated from primary-cultured melanocytes
from the foreskin of healthy children [25] as a source for
mouse xenografts.Establishment of a melanoma xenograft nude mouse
model
A total of 25 4–5 w BALB/c strain nude mice (18–20 g)
(Beijing HFK Bioscience Co, Ltd, Beijing China) (Animal
license number: SCXK 2009–0004; Beijing) were housed
and raised in the laboratory animal center of the
Affiliated Cancer Hospital of Sun Yat-sen University.
The treatment and use of animals during the study was
approved by the Animal Ethics Committee of Sun
Yat-sen University.
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each: normal human epidermal melanocytes (HEM),
human dermal melanoma cells (A375-WT), G6PD-
deficient A375 cells (A375-G6PDΔ), A375-G6PDΔ cells
with overexpression of normal G6PD cDNA (A375-
G6PDΔ-G6PD-WT), and A375-G6PDΔ cells with
overexpression of mutant G6PD cDNA (A375-G6PDΔ-
G6PD-G487A). Cells in the log-phase stage of growth
were harvested and digested into single cells using 0.25%
pancreatin. Cells were washed with Dulbecco’s Modified
Eagle Medium (DMEM) without serum. A volume of 1
ml of each cell type (1.5×106/ml) was injected intrader-
mally into the left axilla of the mice subjects. After
seeding, liquid absorption at the injection site, tumor
growth (volume and weight), and mouse survival were
observed. Tumor volume was measured on days 5, 7, 12,
16, 19, 21, and 23 post-injection. On day 23, all mice
were sacrificed, and tumors were isolated for determi-
nation of weight and volume.
The largest (a) and smallest diameters (b) of each
tumor were measured twice on days 5, 7, 12, 16, 19, 21,
and 23 to estimate tumor volume (V) using the formula
V = 0.52 × a2 × b [26]. Mean tumor volumes were used
to plot tumor growth curves for each group of mice.
Immunohistochemistry
Immunohistochemistry was performed to determine
associations between the G6PD expression in various
experimental groups, tumor growth, and pathological
changes.
Tumor samples were fixed in 4% formaldehyde,
embedded in paraffin wax, and then cut into 4 μm
sections using a microtome. The sections were stained
with hematoxylin and eosin (HE).
Fixed tumor samples were prepared into 30 μm frozen
sections and incubated with 2% goat serum at 37°C for
20 min, followed by incubation with rabbit-anti-G6PD
(1:500, Boster, China) at 4°C overnight. After washing
with PBS, the sections were incubated with horseradish
peroxidase (HRP)-conjugated goat anti-rabbit IgG
(HRP-IgG) at 37°C for 30 min and colored with 3,3′-
Diaminobenzidine (DAB) at room temperature. PBS was
substituted for the rabbit-anti-G6PD antibody in nega-
tive control subjects. The number of cells positive for
G6PD was then calculated.
Determination of G6PD activity
Tumor samples (20 mg) were homogenized with 5 ml of
PBS at 4°C and centrifuged at 5000 r/min for 3 min. The
supernatant (30 μl) was treated with a G6PD Activity
Assay Kit reagent (BioVision, USA) according to the
manufacturer’s instructions. The optical density (OD
value, A1) of the positive control supplied by the kit
was measured at 450 nm using a U-1800 ultravioletspectrophotometer (Hitachi, Japan). After 30 min at
37°C the OD value (A2) was measured a second time.
The kit’s standard reagent, nicotinamide adenine
dinucleotide hydride (NADPH), was diluted 3 times, and
the standard curve was plotted. A1 and A2 were
introduced into the standard curve to generate the total
NADH (B). The G6PD activity was then calculated using
the formula: G6PD activity (mU/ml) = B/30 × V ×
dilution times.Extraction of total RNA, reverse transcription, and
quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was used to
quantify the expression of G6PD mRNA in the experi-
mental groups. Tumor samples (60 mg) were ground
under liquid nitrogen, lysed with 1 ml of Trizol (Takara,
Japan), and total RNA was extracted using Trizol
(Invitrogen, USA). Total RNA (2 μg) was added to the
tumor extract with Moloney Murine Leukemia Virus
Reverse Transcriptase (MMLV-RT, Takara, Japan) to
synthesize cDNA, and the reverse transcript was used as
the template for qRT-PCR using a Tower qRT-PCR
system (Analytic Jena, Germany). The qRT-PCR was
conducted using 2×Mix SYBR Green I (Biosea, USA)
(10 μl), primer (0.25 μl, 10 pmol/L), template DNA
(1 μl), and sterile water (8.5 μl). All PCR reactions
included initial denaturation and multiple cycles at (95°C
for 3 min); 39 cycles at 95°C for 10 s, 55°C for 10 s, and
72°C for 30 s; followed by 95°C for 10 s, 65°C for 5 s, and
a final 95°C for 15 s. The primer for each gene was synthe-
sized by Invitrogen (USA), and the sequences were deter-
mined (Table 1).Western blot
Tumor samples were lysed for 30 min in CytoBuster
Protein Extraction Buffer (Novagen, USA) and centri-
fuged at 12000 rpm. The supernatant was collected, total
protein was measured, and 50 μg was used for 10%
sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE). The protein was then transferred to a
nitrocellulose (NC) membrane and sealed with Tris-
Buffered Saline Tween-20 (TBST) containing 5% non-fat
milk powder. The membrane was subsequently incu-
bated with rabbit anti-human STAT3, P-STAT3, STAT5,
and P-STAT5 proteins and mouse anti-human β-actin
(1:500 to 1:1000, Boster) at 4°C overnight. After washing
in TBST, the membrane was incubated with HPR con-
jugated secondary antibodies (1:6000) at 25°C, and the
protein quantity was determined using electroche-
miluminescence (ECL) technique (BestBio, USA). The
results were photographed using the JS Gel Imaging
System (Peiqing, China) and the grey density was
calculated using SensiAnsys software (Peiqing, China).
Table 1 Real-time PCR primer sequences
Gene Primer Sequence of primer Length of sequence (Base) Length of amplified product (bp)
G6PD G6PD-F 5′TGAGCCAGATAGGCTGGAA3′ 19 225
G6PD-R 5′TAACGCAGGCGATGTTGTC3′ 19
CyclinD1 CyclinD1-F 5′CGGTAGTAGGACAGGAAGTT3′ 20 120
CyclinD1-R 5′CTGTGCCACAGATGTGAAGT3′ 20
Fas Fas-F 5′GCCACCGACTTTAAGTTTGC3′ 20 102
Fas-R 5′CGAGCTCACTTCCTCATCCT3′ 20
STAT3 STAT3-F 5′CACCCGCAATGATTACAGTG3′ 20 126
STAT3-R 5′CGGTCTGACCTCTTAATTCG3′ 20
STAT5 STAT5-F 5′CACCCGCAATGATTACAGTG3′ 20 126
STAT5-R 5′CGGTCTGACCTCTTAATTCG3′ 20
β-actin β-actin-F 5′TGGCACCCAGCACAATGAA3′ 20 186
β-actin-R 5′CTAAGTCATAGTCCGCCTAGAAGCA3′ 25
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Statistical analyses were performed using SPSS statistical
software version 13.0 (IBM, USA). One-way analysis of
variance (ANOVA) with 5 levels was used with a
completely randomized design, and the homogeneity of
variance was tested. A q test (Student-Newman-Keuls)
was used to compare the differences between groups,
and a rank sum test was performed to randomly
compare treatments. A P-value of less than 0.05 was
considered statistically significant (P < 0.05). Values
were expressed as means ± standard deviation
(mean ± SD).Figure 1 Identification of tumor cell lines. A, Determination of mRNA e
of G6PD protein in various cell lines; C, Determination of G6PD activity in vResults
Construction and identification of cell lines
After multiple freeze-thaw cycles (≥ 20), fluorescent pro-
tein [24] was stably expressed in A375-G6PDΔ, A375-
G6PDΔ-G6PD-WT, and A375-G6PDΔ-G6PD-G487A
cells, which were morphologically normal (data not
shown). The expression of G6PD mRNA, protein quan-
tity, and G6PD activity were all higher in A375 cells than
those in normal HEM cells. After G6PD knockdown, the
expression of G6PD mRNA, G6PD protein, and enzyme
activity were significantly down-regulated (P < 0.01). In
contrast, the G6PD mRNA, protein expression, andxpression of G6PD in various cell lines; B, Determination of expression
arious cell lines.
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normal or G6PD deficient gene was introduced into
A375-G6PDΔ cells. A375-G6PDΔ, A375-G6PDΔ-G6PD-
WT, and A375-G6PDΔ-G6PD-G487A cell lines were
successfully established (Figure 1).
Effect of G6PD deficiency on tumor formation in nude
mice injected with A375 cell lines
Tumor formation was observed in 2 of 5 mice injected
with A375-G6PDΔ cells. These tumors were the last to
form and grew the slowest among the treatment groups.
The fastest tumor growth was observed in the A375-
WT cell group (Figure 2). Tumor formation was
observed 12 d after injection of cells with G6PD defi-
ciency. Tumor sizes observed in the G6PD deficiency
group (A375-G6PDΔ) were significantly smaller than
those observed in the other groups at 12 to 23 d post-
injection (P < 0.05). Tumors presence was observed at 7
d post-injection in A375-WT cells, and tumor size was
significantly greater in this group than in other groups at
16 days post-injection (P < 0.05).
The smallest tumors at 23 d were observed in the
G6PD deficiency group (P < 0.05), while the largestFigure 2 Tumor formation and growth of 4 tumor cells in nude mice. A
melanoma cells (A375-WT), G6PD-deficient A375 cells (A375-G6PDΔ), A375-G6
G6PD-WT) and A375-G6PDΔ cells with overexpression of mutant G6PD cDNA
tumor size was measured on days 7, 12, 16, 19, 21 and 23 post-injection, and
photographed on day 23 (B), and then sacrificed. The tumors were isolated, atumors were in the A375-WT cell group (P < 0.05).
There was no significant difference in tumor weights
between the A375-G6PDΔ-G6PD-G487A and A375-
G6PDΔ-G6PD-WT cell groups (P > 0.05), but both
exhibited tumors that were larger than those observed in
the G6PD deficiency group (P < 0.05, Figure 2C).
Pathological staining results showed that tumors in
the A375-WT cell group appeared to be more malignant
than those observed in other groups. Tumor cells taken
from the A375-G6PDΔ group exhibited the most benign
changes compared with other groups (Additional file 1:
Table S1 and Additional file 2: Figure S1). No metastasis
was observed in either the liver or lungs in any groups,
as determined via microscopic techniques.
G6PD expression and enzyme activity in nude mice tumor
tissues
Immunohistochemistry demonstrated that the largest
number of G6PD-positive cells were present in the
A375-WT cell group, while the amount of G6PD-
positive cells was significantly reduced in the A375-
G6PDΔ cell group (Figure 3A, 3C). Similarly, qRT-PCR
indicated that the level of G6PD mRNA detected in thefter normal human epidermal melanoma cells (HEM), human dermal
PDΔ cells with overexpression of normal G6PD cDNA (A375-G6PDΔ-
(A375-G6PDΔ-G6PD-G487A) were injected into the nude mice. The
the tumor volume growth curve (A) was plotted. The nude mice were
nd the weights (C) and volume of the tumors were measured (D).
Figure 3 G6PD protein and mRNA expression and activity in tumor tissues of nude mice from different experimental groups.
A, Paraffin-embedded sections of the tumor tissues of nude mice from different groups were made and the G6PD expression is determined
using immunohistochemistry (400×); B, Immunohistochemistry reveals the G6PD-positive cells in tumor tissues; C, Changes of G6PD activity. n, a,
b, c and d indicate statistically significant differences, P < 0.05. n, vs. HEM cells group; a, vs. A375-WT cells group; b, vs. A375-G6PDΔ cells group; c,
vs. A375-G6PDΔ-G6PDWT cells group; d, vs. A375- G6PDΔ-G6PD-G487A cells group. D, mRNA expression of G6PD detected by qRT-PCR.
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with that observed in the A375-G6PDΔ group (P < 0.05,
Figure 3D). The highest G6PD activity was observed in
the A375-WT cell group, followed consecutively lower
activities observed in the A375-G6PDΔ-G6PD-WT and
A375-G6PDΔ-G6PD-G487A cell groups. The lowest
G6PD activity was observed in the A375-G6PDΔ cell
group (P < 0.01, Figure 3B), demonstrating the associ-
ation of G6PD with melanoma formation and growth in
nude mice.
Correlation of G6PD in tumor tissues with cell cycle
protein expression
The qRT-PCR showed that mRNA levels of cyclin D1 in-
creased by 31-fold in the A375-WT cell group compared
with the lowest observed levels in the A375-G6PDΔ cell
group (P < 0.05, Figure 4D). Immunohistochemistry also
suggested that the protein levels of Cyclin E, p53, and
S100A4 in the A375-G6PDΔ group decreased by 77%,60%, and 74%, respectively, compared with levels
observed in the A375-WT group (Figure 4, Additional
file 3: Figure S2, Additional file 4: Figure S3, Additional
file 5: Figure S4). Both the mRNA level of cyclin D1 and
the protein levels of these three genes in A375-G6PD
Δ-G6PD-WT and A375-G6PDΔ-G6PD-G487A cell
groups were determined to be partially recovered.
Correlation of G6PD in tumor tissues with apoptosis-
related protein expression
Immunohistochemistry showed that the expression of
apoptosis inhibitory factors Bcl-2 and Bcl-xL was signifi-
cantly down-regulated in the A375-G6PDΔ cell group,
while the expression of Fas protein increased by 72%
compared with expression levels observed in the A375-
WT cell group (Figure 5, Additional file 6: Figure S5,
Additional file 7: Figure S6, Additional file 8: Figure S7).
Protein expression data for Fas was also supported by
the Fas mRNA levels detected by qRT-PCR (Figure 5D).
Figure 4 Determination of cell cycle-related genes in tumor tissues of nude mice from different experimental groups. A, amounts of
cyclin E-positive cells in tumor tissues. B, amounts of p53-positive cells in tumor tissues. C, amounts of S100A4-positive cells in tumor tissues. n, a,
b, c and d indicate statistically significant differences (P < 0.05), n vs. HEM; a vs. A375-WT; b vs. A375-G6PDΔ; c vs. A375-G6PDΔ-G6PDWT; d vs.
A375-G6PDΔ- G6PD-G487A. D, mRNA expression of cyclinD1 detected by qRT-PCR.
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G6PDΔ-G6PD-G487A cell groups remained at moderate
levels.
Expression of STAT3 and STAT5 in tumor tissues
Western blot analysis results showed that STAT3, P-
STAT3, STAT5, and P-STAT5 proteins decreased by
47%, 65%, 38%, and 67%, respectively, in the A375-
G6PDΔ group as compared with results observed in the
A375-WT group. Expressions of these proteins were
observed to be partially restored in the A375-G6PD
Δ-G6PD-WT and A375-G6PDΔ- G6PDG487A treated
groups (Figure 6). The mRNA levels of STAT3 and
STAT5 were detected by qRT-PCR, providing further
support for these results (Figure 6D, 6E). Data presented
in Figures 6B and 6C was generated from the average
western blot data of all animal tissues in each group.
Discussion
G6PD was previously shown to be highly expressed in
human melanoma cells, exhibiting a close relationship to
the growth and proliferative phenotype of tumor cells
[24], although no in vivo study has confirmed this find-
ing. Moreover, the underlying mechanism behind this
correlation may be important in developing a complete
understanding of the pathogenesis of melanoma and
providing critical experimental evidence for the deve-lopment of improved clinical treatment options. In the
current study, as expected, expression and activity of
G6PD showed a positive correlation with melanoma
weight, growth, and differentiation. These findings
suggest that G6PD expression in the A375 cell line plays
an important role in tumor growth and proliferation.
These findings are consistent with previous reports
noting elevated expression or activity of G6PD in tumor
cells [11-18]. Furthermore, expression and activity of
G6PD was shown to be positively correlated with mRNA
and protein expression of cyclins D1 and E, p53, and
S100A4. These findings suggest that G6PD can regulate
cell cycle through its effect on these factors, thus indi-
rectly regulating melanoma growth.
Cyclin D1 accelerates the G1/S phase transition and
promotes cell growth and division. Cyclin D1 over-
expression is considered to be an important factor in the
promotion of tumor occurrence and development, where
it is also associated with reduced response to growth
factors [27,28]. Elevated cyclin D1 gene expression in
melanoma cells revealed that cyclin D1 was the key
protein promoter of A375 cell proliferation and its
overexpression can cause cell proliferation out of control
which promotes tumor malignancy. Cyclin E is synthe-
sized initially in the G1 phase, and expression increases
in mid-G1 phase. Thereafter, cyclin E expression sharply
increases and reaches its peak at the G1/S junction,
Figure 5 Determination of cell apoptosis genes in tumor tissues of nude mice from different experimental groups. A, amounts of
Bcl-2-positive cells in tumor tissues B, amounts of Bcl-xl-positive cells in tumor tissues. C, amounts of Fas-positive cells in tumor tissues and n,
a, b, c and d indicate statistically significant differences (P < 0.05), n vs. HEM; a vs. A375-WT; b vs. A375-G6PDΔ; c vs. A375-G6PDΔ-G6PDWT; d vs.
A375-G6PDΔ- G6PD-G487A. D, mRNA expression of Fas detected by qRT-PCR.
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Immunohistochemical staining revealed few cyclin E-
positive cells in the HEM group and significantly
elevated cyclin E expression in the A375-WT group,
suggesting that cyclin E is an important factor in mela-
noma occurrence and consistent with report by Bales E
[30]. Furthermore, expression levels of cyclin D1 and E
are positively correlated with expression of G6PD and its
activity. These findings have indicated the vital regula-
tion role of G6PD in uncontrolled cell proliferation and
resultant malignant transformation in melanomas.
The tumor suppressor protein p53, a crucial regulator
of the cell cycle in multicellular organisms, is also not
expressed in certain cancers, including skin melanomas.
It is, however, overexpressed in invasive melanomas with
a high proliferative index [31,32]. Elevated p53 expres-
sion observed in A375 cells correlated well with high
G6PD activity, suggesting that protein p53 is promoted
by G6PD, which is consistent with study by Murtas et al.
[33]. Jiang P found that the protein p53 affect the growth
and invasion of melanoma cells in nude mice by inter-
fering with the pentose-phosphate pathway in tumor
cells [34]. These results suggest p53 may affect glucose
metabolism in human melanoma when the activity of
G6PD is interfered. S100A4 is a protein closely related
to cellular differentiation and tumor occurrence, metas-
tasis, and prognosis. S100A4 binds to the p53 proteinand restricts the function of the G-S restriction point in
the cell cycle. It may also be associated with uncon-
trolled entry in the M phase by bypassing the G2-M
restriction point [35,36]. The present study showed that
the level of S100A4-positive cells correlated well with
p53, G6PD activity, and tumor growth, suggesting that
G6PD affects p53 activity, thus also impacting melanoma
occurrence and metastasis by regulation of S100A4
expression.
G6PD also showed a positive correlation to mRNA
and protein expression of cell apoptosis inhibitory
factors Bcl-2 and Bcl-xl and a negative correlation to
Fas. Fas can be used as a marker to escape apoptosis by
malignant cells. The immune escape mechanism emplo-
yed by malignant melanomas involves actively attacking
cytotoxic T lymphocytes (CTL) that express Fas to
escape from apoptosis [37]. The Bcl-2 protein family
affects apoptosis by regulating mitochondrial and endo-
plasmic reticulum stress-induced apoptotic pathways
[38,39]. The proportion of apoptosis-inhibitory protein
(Bcl-2) and apoptosis-promoting protein (Bax) deter-
mines the rate of apoptosis occurrence if cells are stimu-
lated by apoptotic signals. Higher Bax/Bcl-2 ratios result
in relatively higher sensitivity to CD95/Fas-mediated
apoptosis [40]. In the present study, lower Fas expres-
sion in the A375-WT group and elevated Fas expression
in the A375-G6PDΔ group with the G6PD knockout
Figure 6 Determination of STAT-3 and STAT-5 expression in tumor tissues. Expression of STAT-3 and STAT-5 proteins and qualitative (A)
and semi-quantitative analyses (B and C) of their phosphorylations. 1, HEM; 2, A375-WT; 3, A375-G6PDΔ; 4, A375-G6PDΔ-G6PDWT; 5, A375-
G6PDΔ-G6PD-G487A. STAT3 is persistently activated in A375-WT cells. Compared with the HEM group, higher P-STAT3 expression is observed in
the A375-WT cells group. Following knockdown of G6PD in wild-type A375 cells, the expression of both STAT3 and P-STAT3 decreases. The mRNA
expression of STAT3 (D) and STAT5 (E).
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inhibitory proteins Bcl-2 and Bcl-xL in the A375-G6PD
Δ group. Similarly, high expression was observed in the
A375-WT group, suggesting that G6PD may regulate
cell apoptosis of melanoma through apoptosis-related
factors Fas, Bcl-2, and Bcl-xL. Cumulatively, G6PD has a
varied mechanism of action, affecting the levels of
numerous other proteins associated with cell cycle regu-
lation, thus promoting the development of malignancies.
The STAT pathway is well-down for its association
with proliferation of malignant melanoma, escape from
apoptotic signals, tumor invasion and angiogenesis [41].
More importantly, activation of STAT is the key factor
for development of melanoma [42]; silencing of STAT3
using short hairpin RNA (shRNA) inhibits the growth of
melanoma in tumor-bearing mice [43].
STAT3 can down-regulate Bcl-xL expression and in-
duce apoptosis in human melanoma A2058 and Jw cell
lines [44]. In metastatic melanoma, the expression of
phosphorylated STAT3 is positively correlated with Bcl-
xL expression [45]. Suppression of STAT5 protein in hu-
man melanoma A375 cells significantly down-regulatesBcl-2 expression [46], while activation of STAT5 up-
regulates Bcl-xL expression [42]. This indicates that
STAT5 is an important anti-apoptotic factor [22,46].
Similarly, the present study indicated that STAT3 and
STAT5 were positively correlated with Fas expression
and negatively correlated with expression of Bcl-2 and
Bcl-xL. Leslie et al. [47] demonstrated that Cyclin D1
mRNA levels were significantly increased in tumor cell
lines that had excessive activation of the STAT3 signal-
ing pathway, while mutagenesis of STAT3 binding sites
within the cyclin D1 promoter region significantly
inhibited the transcription of the Cyclin D1 gene. Cyclin
D1 level was also positively correlated with STAT3 level
in our study. Altogether, it suggests that the STAT3/
STAT5 pathway could possibly be involved in the
mechanism behind cell cycle abnormalities and cell
apoptosis regulation.Further mechanistic studies, how-
ever, will be required to verify this mechanism.
Conclusion
G6PD is involved in the growth, proliferation, and apop-
tosis of neoplastic tumors in nude mice models of
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http://www.biomedcentral.com/1471-2407/13/251melanoma. Furthermore, the tumor malignancy was
observed to be in accord with G6PD protein expression.
Higher expression of G6PD protein promoted the
survival and proliferation of neoplastic tumors in nude
mice models of melanoma (A375 cells) through the up-
regulation of cyclin D1 and cyclin E, P53 and S100A4
protein expression. In this model, a deficiency of G6PD
proteins in A375-G6PDΔ cells promoted cell apoptosis
through down-regulation of the expressions of Bcl-2 and
Bcl-xL and up-regulations of the expression of Fas. The
correlation of G6PD expression and tumor growth
corresponded with STAT3/STAT5 expression, although
further experiments will be required to confirm the direct
regulatory role of G6PD on this pathway. Because of the
broad affects of G6PD, it may provide an excellent target
for the development of improved treatment methods and
prognostic indicators for melanoma patients.
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